<DOC>
	<DOCNO>NCT02287974</DOCNO>
	<brief_summary>To study effect stem cell therapy autologous mononuclear bone marrow , autologous progenitor endothelial CD133 cell bone marrow autologous mesenchymal stem cell adipose tissue inflammatory cytokine , resistance insulin decrease need insulin , besides evaluates safety , viability efficiency intra-arterial infusion stem cell diabetic patient type 2 CLI .</brief_summary>
	<brief_title>Clinical Trial I/II Opened , Randomized Controlled Study Use Stem Cells Therapy Insulinized Diabetic Patients Type 2 With Critical Ischemia Lower Limbs ( CLI ) : Study Needs Insulin</brief_title>
	<detailed_description>To study effect stem cell therapy autologous mononuclear bone marrow , autologous progenitor endothelial CD133 cell bone marrow autologous mesenchymal stem cell adipose tissue inflammatory cytokine , resistance insulin decrease need insulin , besides evaluates safety , viability efficiency intra-arterial infusion stem cell diabetic patient type 2 . Diabetic patient include critical ischemia chronicle least low member limb ( CLI ) without possibility revascularization . 48 evaluable patient include , 36 patient include experimental group ( 12 every cellular group ) 12 group control conventional treatment . The population study constitute 48 evaluable patient .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>1 . Age ≥18 ≤ 85 year 2 . Diabetic type 2 , treatment insulin least 3 previous month . 3 . Vascular disease infrapopliteal atherosclerotic severe degree ( Patients category RutherfordBecker ≥ 4 ) , pretty bilateral . The critical ischemia foot define persistent / persistent pain need analgesia / heal present sore &gt; 4 week , without evidence improvement conventional therapy / walk test 16 minute two ergometries separate least 2 week / index ankle arm rest &lt; 0,8 . 4 . Impossibility revascularization surgical endovascular I fail surgery revascularization perform least 30 day , persistence entry phase critical ischemia 5 . Life expectancy &gt; 2 year . 6 . Major amputation foreseen member next 6 month incorporation . 7 . Normal Biochemical bone marrow parameter define : Leukocytes ≥ 3000 Neutrophils ≥ 1500 Platelets ≥ 140000 AST/ALT ≤ 2,5 standard range institution Creatinine ≤2,5 mg/dl explanation creatinine ≤ 30 ml/min ( MDRD4 ) 8 . The woman fertile age obtain negative result pregnancy test realize moment incorporation study promise use contraceptive method medically approve study last . 9 . Patients give Informed Consent write participation study . 10 . Patients take part another clinical trial last 3 month incorporation . 1 . Precedent neoplasia hematologic disease ( disease myeloproliferative , syndrome myelodysplasic leukaemia ) last 2 year . 2 . Major previous amputation . 3 . Patients arterial uncontrolled hypertension ( define arterial tension &gt; 180/110 one occasion ) . 4 . Cardiac severe insufficiency ( NYHA IVth ) Fraction Ejection leave ventricle ( FAITH ) low 30 % . 5 . Patients ventricular malignant arrhythmia unstable angina . 6 . Diagnosis venous deep thrombosis 3 previous month . 7 . Patients genotype DD ECA genotype E4 apo E. 8 . Concomitant therapy include oxygen hyperbaric , vasoactive substance , agent angiogenesis inhibit CoxII . The agent use allow antiplatelets . 9 . Index corporal mass &gt; 40 Kg/m2 . 10 . Patients diagnosis alcoholism moment incorporation . 11 . Proliferative Retinopathy without possibility treatment . 12 . Diabetic Nephropathy haemodialysis 13 . Concomitant disease reduce life expectancy le 1 year . 14 . Impossibility foreseen obtain inhaled one 100ml bone marrow . 15 . Infection HIV , Hepatitis B Hepatitis C. 16 . Impede followup . 17 . ACV heart attack myocardium last 3 month 18 . Anaemia ( Haemoglobin &lt; 7.9 g/dl ) 19 . Patients treat cellular therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>